Marie-Cécile Wetzel

Title: Marie-Cécile Wetzel: Innovator in Antibody Research

Introduction

Marie-Cécile Wetzel is a prominent inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-like binding proteins. His work focuses on innovative solutions for cancer treatment.

Latest Patents

Marie-Cécile Wetzel holds a patent for "Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123." This invention involves antibody-like binding proteins that specifically bind to CD3 and at least one additional antigen, such as CD123. The patent also covers anti-CD3 and anti-CD123 antibodies, along with pharmaceutical compositions that utilize these proteins for cancer treatment. Furthermore, it includes isolated nucleic acids, vectors, and host cells that encode these antibodies, highlighting their potential as diagnostic tools.

Career Highlights

Marie-Cécile Wetzel is associated with Sanofi, a leading global healthcare company. His work at Sanofi has been instrumental in advancing therapeutic options for patients suffering from cancer. His innovative research has positioned him as a key figure in the biotechnology sector.

Collaborations

Marie-Cécile Wetzel has collaborated with notable colleagues, including Jana Albrecht and Cédric Barriere. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapies.

Conclusion

Marie-Cécile Wetzel's contributions to antibody research and cancer treatment exemplify the impact of innovation in biotechnology. His work continues to pave the way for new therapeutic approaches that can significantly improve patient outcomes.